Navigation Links
Mylan Schedules First Quarter 2010 Financial Results Conference Call and Live Webcast

PITTSBURGH, April 22 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, April 29, 2010, at 10 a.m. ET, to review the company's financial results for the first quarter 2010, which ended March 31, 2010. Mylan will release its financial results on April 29 before the market opens.

The dial-in number to access the call is 877.627.6581 or 719.325.4800 for international callers. A replay, available for approximately seven days, will be available at 888.203.1112 or 719.457.0820 for international callers with access pass code 7640622.

To access a live webcast of the call, please log on to Mylan's Web site ( at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on for approximately seven days.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Actigall(R)
2. Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
3. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
4. Mylan Receives Approval for Generic Version of GoLytely(R)
5. Mylan Declares Quarterly Preferred Stock Dividend
6. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
7. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
8. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
9. Mylan Added to NASDAQ-100 Index
10. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
11. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):